Ixekizumab is the second interleukin 17 blocker on the market and probably the 7th biologic drug for psoriasis and psoriatic arthritis. It is administered by self-injection.
Ixekizumab inhibits a cytokine, IL 17.
| Indication | Dose | |||
| Psoriasis | 160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, and then 80 mg every 4 weeks | |||
| Psoriatic arthritis (PsA) | 160 mg.once then 80 mg. q 4 weeks | |||
| Ankylosing spondylitis | 160 mg once, followed by 80 mg every 4 weeks | |||
| nrAxSpA |
|
| Common side effects | % | ||
| side effect 1 | # | ||
| Side effect 2 | # | ||
| Side effect 3 | # |